Laser Photonics Corp

This management proposal requests shareholder approval of the March Warrant Inducement Agreement entered into on March 15, 2026 with holders of existing Series A and Series B warrants. The agreement provides the warrant holders an inducement to exercise by offering replacement Series A-3 and A-4 warrants exercisable at a reduced exercise price of $1.08 per share (down from $3.40), thereby accelerating potential cash proceeds to the Company; the company received gross proceeds of $1,483,520.40 in connection with the inducement. The replacement warrants require registration of the 2,747,260 underlying shares via an S-1 that must be filed within 30 days and declared effective within prescribed timelines, with filing/timing covenants and associated restrictions on issuance of other securities and variable rate transactions for limited periods. Management frames the transaction as necessary to fund the Company's business plan, increase near-term liquidity and potentially enable further financing if the new warrants are exercised; the Board recommends a FOR vote, stating that proceeds have funded operations and could result in additional financing. Key governance considerations include dilution to existing shareholders from issuance and exercise of nearly 2.75M shares, the material reduction in exercise price (from $3.40 to $1.08) which transfers value to warrant holders, and transferability/term differences between Series A-3 and A-4 (longer five-year term for A-3 vs eighteen months for A-4) which affect the timing of potential dilution. The requirement to register shares and the company's related filing covenants create execution risk (including potential cash penalties per the April agreement precedent) and timeline constraints; investors should weigh whether the immediate liquidity benefit and operational funding justify the dilution and contractual restrictions. The Board’s recommendation is grounded in the immediate proceeds and anticipated ability to file the registration statement; however, shareholders should consider potential long-term share count impacts, the control implications if major existing holders participate, and whether the reduced strike price aligns with shareholder interests given the company’s recent financing and related party transactions.

This management proposal requests shareholder approval of the April Warrant Inducement Agreement entered into on April 26, 2026 with holders of existing Series A-1 and Series A-2 warrants. The agreement provides the warrant holders new Series A-5 and A-6 warrants exercisable at $0.975 per share (down from the original $0.70 exercise price of the existing warrants) in exchange for cash, yielding gross proceeds of $4,000,559.50 to the Company. The transaction requires the Company to file a resale S-1 to register 11,430,170 shares underlying the new warrants within 30 days and be subject to effectiveness timing constraints and related filing covenants; failure to meet these timelines may trigger cash penalties under the agreement. The agreement includes beneficial ownership limitations on exercises (4.99% or 9.99% at holders’ election), placement agent fees and warrants to H.C. Wainwright, and restrictions on issuing other securities or entering variable rate transactions for set periods. Management argues the financing provides significant near-term liquidity to fund operations and could lead to further financing upon exercise; the Board recommends a FOR vote. Material considerations for shareholders include substantial dilution risk (over 11 million underlying shares), the grant of placement agent warrants and fees, potential cash penalties for filing delays, and the reduced exercise price that accelerates potential dilution; these items should be considered against the immediate capital infusion and strategic need for funding.